Newsletters

Please click on the links below to view our electronic newsletters. In addition, please sign-up below with your email address to receive the newsletter directly to your inbox.

Joni Henderson 10/21/24 Joni Henderson 10/21/24

C2N at CTAD 2024 in Madrid

Joni Henderson 9/4/24 Joni Henderson 9/4/24

JAMA Published Landmark Clinical Study on Alzheimer’s Disease Diagnosis Using the PrecivityAD2™ Blood Test

Joni Henderson 7/16/24 Joni Henderson 7/16/24

C2N at AAIC in Philadelphia July 28–Aug. 1

Lee Q 10/18/23 Lee Q 10/18/23

Join our C₂N Diagnostics team at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) October 24 – 27 in Boston

Guest User 6/30/23 Guest User 6/30/23

C₂N Diagnostics, a leader in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2023 AAIC in Amsterdam July 16–20

Guest User 11/17/22 Guest User 11/17/22

Join our C₂N Diagnostics team at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco, November 29 – December 2

Joni Henderson 10/21/22 Joni Henderson 10/21/22

C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments

Joni Henderson 7/25/22 Joni Henderson 7/25/22

Join our C₂N Diagnostics team at Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, July 31 – August 4

Lee Q 7/13/22 Lee Q 7/13/22

C₂N Diagnostics Takes Major Strides in Advancing Brain Health Diagnostics

Lee Q 3/14/22 Lee Q 3/14/22

C₂N Achieves More Advancements in Brain Health Diagnostics

Guest User 10/28/21 Guest User 10/28/21

Two Independent Research Studies Bolster Method That C₂N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses

Guest User 4/23/21 Guest User 4/23/21

PrecivityAD™ Test Success Leads to Attention and Growth

Joni Henderson 12/21/20 Joni Henderson 12/21/20

2020 Marks a Year of Achievement

Newsletters

C2N at CTAD 2024 in Madrid

JAMA Published Landmark Clinical Study on Alzheimer’s Disease Diagnosis Using the PrecivityAD2™ Blood Test

C2N at AAIC in Philadelphia July 28–Aug. 1

Join our C₂N Diagnostics team at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) October 24 – 27 in Boston

C₂N Diagnostics, a leader in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2023 AAIC in Amsterdam July 16–20

Join our C₂N Diagnostics team at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco, November 29 – December 2

C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments

Join our C₂N Diagnostics team at Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, July 31 – August 4

C₂N Diagnostics Takes Major Strides in Advancing Brain Health Diagnostics

C₂N Achieves More Advancements in Brain Health Diagnostics

Two Independent Research Studies Bolster Method That C₂N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses

PrecivityAD™ Test Success Leads to Attention and Growth

2020 Marks a Year of Achievement

Company

Resources